The UK and US have announced a significant bilateral deal that will guarantee zero import taxes on UK pharmaceutical products entering the American market.
Agreement Details of the Deal
As part of the deal, the UK has pledged to increase funding on medicines through the public health system. This pledge secures that tariffs on these crucial goods will stay at nothing for a period of 36 months.
This deal follows recent statements to dramatically increase tariffs on patented drug products, with increases floated reaching 100%.
"This agreement with the United Kingdom reinforces the global environment for cutting-edge drugs and introduces much-needed balance to transatlantic drug exports," a release noted.
Trade Significance
Drugs constitute one of the Britain's biggest export categories to the US, which is by far the primary destination for major companies like GSK and AstraZeneca.
Export figures indicate that in the 12 months prior to September, the UK shipped drugs valued at over eleven billion pounds to the US. This figure made up a significant portion of British export trade in that timeframe.
"This deal safeguards jobs, increases capital expenditure and facilitates the UK to emerge as a international leader for medical research," a minister stated.
Detailed British Pledges
The agreement entails several specific changes from the British government:
- Price Threshold Increase: The UK will increase the cost ceiling at which it considers new medicines to be too expensive by a quarter.
- Higher Drug Budget: There is a goal to raise overall NHS spending on drugs from 0.3 percent of GDP to 0.6% over the next decade.
- Refund Ceiling: The sum drug companies must return to the NHS to control costs will be limited at 15%. In the past, rebates exceeded 20%.
Industry Background
The deal takes place against a protracted row between the pharmaceutical industry and the ministers over drug pricing and approval rates.
This friction were exacerbated by arguments that American patients were paying several times more for the identical medicines than people in the UK and Europe.
In recent months, several significant pharmaceutical investments in the UK have been paused or abandoned, while major funding commitments have been announced toward projects in the United States.
A senior figure stated that the NHS must invest a greater share on drugs, noting that its budget allocation on drugs had shrunk as a proportion of its resources over the past decade.
